FPHAX Fees and Costs — Select Pharmaceuticals Portfolio
Data updated: 2026-07-24
The net expense ratio is 0.67%: a 0.65% management fee plus 0.02% other expenses. There are no sales loads or redemption fees. In fiscal 2026 the fund paid $633K in broker commissions, 0.0524% of average net assets, and portfolio turnover was 77%.
FPHAX Fees and Expenses
Annual operating expenses and sales charges of FPHAX. Prospectus, as of April 30, 2026.
| Annual operating expenses | |
|---|---|
| Management fee | 0.65% |
| 12b-1 fee | 0.00% |
| Other expenses | 0.02% |
| Gross expense ratio | 0.67% |
| Fee waiver | — |
| Net expense ratio | 0.67% |
| Sales charges | |
|---|---|
| Max front load | — |
| Max deferred load | — |
| Redemption fee | — |
| Expense limitation in place (N-CEN) | Yes |
| Fees waived or reduced during the year | No |
| Waived fees subject to recoupment | No |
FPHAX Costs Over Time
On $10,000 invested in FPHAX, assuming 5% a year before costs, total costs come to $454 over 5 years, cutting the return by 0.76% a year. Illustration, not a forecast: it assumes today's net expense ratio throughout (a fee waiver may end).
| $10,000 invested | Sell after 1 year | Sell after 3 years | Sell after 5 years |
|---|---|---|---|
| Value before costs | $10,500 | $11,576 | $12,763 |
| Fund expenses (net expense ratio 0.67%) | $70 | $220 | $383 |
| Trading costs (broker commissions) | $6 | $17 | $30 |
| Lost growth on money paid in costs | $0 | $12 | $42 |
| Total costs | $76 | $249 | $454 |
| Value after costs | $10,424 | $11,327 | $12,308 |
| Impact on return, per year | 0.76% | 0.76% | 0.76% |
FPHAX Trading Costs
Brokerage costs reported on SEC Form N-CEN for the fiscal year ending February 28, 2026.
- Explicit cost rate (commissions ÷ average net assets): 0.0524%
- Total broker commissions: $633K
- Bought from dealers (principal trades, not a cost): $20.5M
- Portfolio turnover (prospectus): 77%
- Securities on loan, average value: $82.2M
- Net income from securities lending: $174K (0.014% of average net assets)
FPHAX Agency Brokers
Commissions paid.
| Broker | Amount | Share |
|---|---|---|
| JPMORGAN CHASE and CO | $88K | 17.81% |
| UBS GROUP AG | $68K | 13.65% |
| CITIGROUP INC | $59K | 12.00% |
| JEFFERIES FINANCIAL GROUP INC | $57K | 11.54% |
| MORGAN STANLEY | $55K | 11.19% |
| GOLDMAN SACHS GROUP INC (THE) | $50K | 9.99% |
| BANK OF AMERICA CORPORATION | $45K | 9.00% |
| VIRTU FINANCIAL INC | $25K | 5.06% |
| BNP PARIBAS | $24K | 4.94% |
| CONDOR TRADING LLC | $24K | 4.81% |
FPHAX Dealer Counterparties
Securities bought directly from dealers (principal trades).
| Broker | Amount | Share |
|---|---|---|
| JEFFERIES FINANCIAL GROUP INC | $7.9M | 38.46% |
| PIPER SANDLER COS | $5.4M | 26.41% |
| GOLDMAN SACHS GROUP INC (THE) | $4.6M | 22.57% |
| JPMORGAN CHASE and CO | $1.8M | 8.65% |
| LEERINK PARTNERS LLC | $492K | 2.40% |
| BANK OF AMERICA CORPORATION | $311K | 1.52% |
For information only. Not investment advice: figures are as reported in SEC filings and may contain errors or be out of date. Past performance does not guarantee future results.